Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an update.
Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend payment and address any other business matters, potentially impacting the company’s financial strategies and stakeholder interests.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, focusing on the medical technology industry. The company specializes in developing and manufacturing medical devices, with a particular emphasis on innovative cardiovascular solutions.
YTD Price Performance: -69.57%
Average Trading Volume: 50,758,466
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$780.6M
For an in-depth examination of 2500 stock, go to TipRanks’ Stock Analysis page.